HOLLISTON, Mass., Jan. 6,
2017 /PRNewswire/ -- Biostage, Inc. (Nasdaq: BSTG),
("Biostage" or the "Company"), a biotechnology company developing
bioengineered organ implants to treat cancers and other
life-threatening conditions of the esophagus, bronchus and trachea,
today announced that Jim McGorry, CEO of Biostage, will be
presenting at the 9th Annual Biotech Showcase conference
being held in San Francisco, CA on
Monday, January 9, 2017 at
2:30 p.m. PT.
As part of his presentation, Mr. McGorry will provide an
overview of the Company and outline Biostage's expected near-term
corporate, regulatory and clinical milestones that will enable the
advancement of its lead product candidate, Cellspan™ esophageal
implant, into human clinical studies in 2017.
A live webcast of the presentation will be available on the
Events page of the Investor Relations section of the Company's
website (www.biostage.com). A webcast replay will be available
approximately two hours after the presentation ends and will be
accessible for 90 days.
About Biostage
Biostage is a biotechnology company
developing bioengineered organ implants based on the company's new
Cellframe™ technology which combines a proprietary biocompatible
scaffold with a patient's own stem cells to create Cellspan™ organ
implants. Cellspan implants are being developed to treat
life-threatening conditions of the esophagus, bronchus or trachea
with the hope of dramatically improving the treatment paradigm for
patients. Based on its preclinical data, Biostage has selected
life-threatening conditions of the esophagus as the initial
clinical application of its technology.
Cellspan implants are currently being advanced and tested in
collaborative preclinical studies. Preclinical, large-animal safety
studies, conducted in compliance with the FDA Good Laboratory
Practice (GLP) regulations, for the Company's Cellspan Esophageal
Implant product candidate are ongoing, in support of Biostage's
goal of filing an Investigational New Drug (IND) application with
the U.S. FDA in the third quarter of 2017. The IND will seek
approval to initiate clinical trials for its esophageal implant
product candidate in humans.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in
this press release are "forward-looking" and are made pursuant to
the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These "forward-looking" statements in this
press release include, but are not limited to, statements relating
to the development expectations and regulatory approval of any of
our products, including those utilizing our Cellframe technology,
by the U.S. Food and Drug Administration, the European Medicines
Agency or otherwise, which expectations or approvals may not be
achieved or obtained on a timely basis or at all; or success with
respect to any collaborations, clinical trials and other
development and commercialization efforts of our products,
including those utilizing our Cellframe technology, which
such success may not be achieved or obtained on a timely basis or
at all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, our ability to
obtain and maintain regulatory approval for our products; plus
other factors described under the heading "Item 1A. Risk Factors"
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 or described in our
other public filings. Our results may also be affected by factors
of which we are not currently aware. The forward-looking statements
in this press release speak only as of the date of this press
release. Biostage expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
Jenene
Thomas
|
Chief Financial
Officer
|
Jenene Thomas
Communications LLC
|
774-233-7321
|
(908)
938-1475
|
tmcnaughton@biostage.com
|
jtc@jenenethomascommunications.com
|
|
|
|
|
Media
Contacts:
|
|
David Schull or
Maggie Beller
|
|
Russo Partners
LLC
|
|
212-845-4271 or
646-942-5631
|
|
Email:
Maggie.beller@russopartnersllc.com
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biostage-to-present-at-biotech-showcase-2017-300386919.html
SOURCE Biostage, Inc.